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The conclusions reached in this review are based on incomplete data. In June 2002, the Melanoma Disease Site Group ([dsg]{.smallcaps}) sent me a draft manuscript of the above paper to review. I specifically recommended that the proposed guideline should reflect the fact that the E1684 trial is *negative* for overall survival benefit for high-dose interferon ([hdifn]{.smallcaps}) at a median follow-up of 12.6 years (one-sided *p* value 0.09, as dictated by the protocol). Dr. John Kirkwood, principal investigator of the E1684 trial, provided a *p* value for overall survival in a letter to *J Clin Oncol* 2001 in response to a letter of mine seeking same. Unfortunately, Dr. Kirkwood, like the [dsg]{.smallcaps}, continues to interpret E1684 as a positive study, in spite of the insignificant *p* value with mature follow-up[\*](#fn1-co13_2p077){ref-type="fn"}. Although the E1684 investigators point to competing causes of death, they have not analyzed disease-specific mortality---or if they have, they have not reported it. They have reported analysis of distant disease-free survival, but this was not a protocol-specified endpoint. During manuscript review, I recommended that the [dsg]{.smallcaps} obtain the 12.6-year follow-up data of E1684 to add to their database and conduct joint analysis with other [ecog]{.smallcaps} trials. The [dsg]{.smallcaps} have not acknowledged this important follow-up data on E1684 in their guideline. In fact, they reiterate that the [ecog]{.smallcaps} 1684 trial detected a significant improvement in overall survival after "prolonged follow-up." This was in spite of being advised that analysis at a median follow-up of 12.6 years is negative (*p* = 0.09) for overall survival benefit. Consequently, we now have two mature [ecog]{.smallcaps} studies of adjuvant [hdifn]{.smallcaps} that are negative for overall survival benefit.

I believe that the results of E1694 are too preliminary to conclude that [hdifn]{.smallcaps} is superior to [gmk]{.smallcaps} vaccine as adjuvant therapy of high-risk melanoma. The importance of mature follow-up is amply demonstrated by the E1684 experience. Indeed, the absence of published follow-up data on the E1694 trial makes one wonder whether the preliminary results are sustained.
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